"Fast-Tracking" a Coronavirus Vaccine Sounds Great. It's Not That Simple: Among the many ways to shorten the vaccine development timeline, approving a treatment based on antibody data -- without completing a phase 3 trial -- could be contentious. This is why

"Fast-Tracking" a Coronavirus Vaccine Sounds Great. It's Not That Simple: Among the many ways to shorten the vaccine development timeline, approving a treatment based on antibody data -- without completing a phase 3 trial -- could be contentious. No matter what happens, Moderna is committed to completing its phase 3 trial, Zaks said, even if the FDA allows its vaccine on the market based on antibody data before the trial is complete. [Extracted from the article]